25 Recruiting Studies at Usc Norris Comprehensive Cancer Center
Active clinical trials at this research center, sourced directly from the NIH registry.
π Los Angeles, California
All research centersRecruiting Studies at Usc Norris Comprehensive Cancer Center
Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)
Acute Myeloid Leukemia
View Study & Checklist βA Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
Advanced Solid Tumors
View Study & Checklist βControlled Low Calorie Diet in Reducing Side Effects and Increasing Response to Chemotherapy in Patients With Breast or Prostate Cancer
Breast Cancer
View Study & Checklist βA Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung
View Study & Checklist βP1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk
Primary Myelofibrosis
View Study & Checklist βA Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
Renal Cell Carcinoma
View Study & Checklist βDose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors
Solid Tumor
View Study & Checklist βA Study of ADRX-0706 in Select Advanced Solid Tumors
Solid Tumors
View Study & Checklist βA Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
Adenocarcinoma, Pancreatic Ductal
View Study & Checklist βA First in Human Study of PLT012 in Participants With Solid Tumor Cancers
Advanced Malignant Solid Tumor
View Study & Checklist βPlacebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor NaΓ―ve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
Advanced Or Metastatic Merkel Cell Carcinoma
View Study & Checklist βStudy of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Advanced Solid Tumors
View Study & Checklist βA Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.
Advanced Solid Tumors Cancer
View Study & Checklist βCore Biopsies for Establishing a Breast Tumor Tissue Repository
Breast Cancer
View Study & Checklist βA Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
Cancer
View Study & Checklist βCombination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma
Cholangiocarcinoma
View Study & Checklist βKQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line)
GIST - Gastrointestinal Stromal Tumor
View Study & Checklist βStudy to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Head and Neck Squamous Cell Carcinoma (HNSCC)
View Study & Checklist βA Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
Immune Thrombocytopenia (ITP)
View Study & Checklist βIvosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
View Study & Checklist βA First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
Melanoma
View Study & Checklist βSafety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
Metastatic Hepatocellular Carcinoma
View Study & Checklist βTT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors
Renal Cell Cancer
View Study & Checklist βA Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors
Triple Negative Locally Advanced Non-resectable Breast Cancer
View Study & Checklist βVisugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure
Unresectable or Metastatic Hepatocellular Carcinoma
View Study & Checklist β